Calidi Biotherapeutics, Inc. · AMEX:CLDI
Calidi Biotherapeutics — Investor Presentation (December 2023)
17 slides from Calidi Biotherapeutics's investor presentation, Dec 19, 2023
Slide 1: Revolutionizing Solid Tumor Treatment
Revolutionizing Solid Tumor Treatment: “ Antonio F. Santidrian, Chief Scientific Officer
Slide 2: Safe Harbor Statement and Disclaimer
Safe Harbor Statement and Disclaimer Forward-Looking Statements “This presentation contains orwardooking statements for purposes ofthe “sae harbor” provisions under the United states Private Securities Utigaton Reform Act of 995, Al tatements other than statements of historia fact, ae statements tha
Slide 3: Challenges of immunotherapies in solid tumors
hallenges of immunotherapies in solid tumors > A Immunosuppressive tumor : i f Immunotherapies upp! @ moa: immunotherapy relies on activated microenvironment immune cells infiltrating and persisting + within tumors to mount an effective Cytokines @ response. ' “A CAR-T & other -_ ee B — 6 Tumor Resi
Slide 4: Solution: Oncolytic viruses
Solution: Oncolytic viruses (o) Oncolytic viruses (OVs) can revolutionize solid tumor treatment by specifically targeting, eradicating tumor cells, and altering the tumor microenvironment (TME) © Calidi selected Ovs. vevaetrs | comp — esac! Haka! Haka anlar rated | compan [nied enoped_—Erwelped_—Nae
Slide 5: Current Obstacles to Oncolytic Virus Therapy
Current Obstacles to Oncolytic Virus Therapy Problems with © The unprotected oncolytic viruses are quickly eliminated by the patient’s immune system Oncolytic Viruses: © This leads to a very limited therapeutic potential HUMAN CLINICAL SCENARIO when using naked virus ACTIVE RAPID INACTIVATION ONCOLY
Slide 6: Calidi's Solution: Stem Cell-Based Platforms to Deliver & Potentiate OV Therapies
CALIDI’S SOLUTION: Stem Cell-Based Platforms to Deliver & Potentiate OV Therapies Stem cells loaded with oncolytic viruses are manufactured in a single off-the-shelf vial _ 1. Stem cell loaded with. Oncolytic Viruses (OV) TARGETED TUMOR
Slide 7: Cell-based virotherapy, the promise of a universal treatment for all tumor types
Cell-based virotherapy, the promise of a universal treatment for all tumor types seal eased omer Targeting All Tumor Cell Types i Beting All Ye Supernova/Neuronova are designed to Cell secretome: attack tumor using multimodal combination (Cytokines, Chemokines) of MOA. we 1- Tumor agnostic 2- Immuno
Slide 8: The power of using a cell-based virotherapy
The power of using a cell-based virotherapy Cell component of virotherapy offers: 1. Protection against humoral immunity © 2. Targeting both, Local and Distant Tumor Sites - ah 3. Immunomodulation These cell-derived components Nz 4. Enhancing Therapeutic Potency play pivotal roles in amplifying (sup
Slide 9: Advantages of Calidi's Technology
Advantages of Calidi’s Technology ® ‘Treatment: CAL1 — naked virus Ee | BC3 (prostate cancer) Feros 3 io) Preclinical in vitro data shows that Vaccinia Virus (VACV) kills tumor cells, Vaccinia virus (VACV) engineered to express red fluorescent protein. Treatment: CALA - naked virus PC3 (prostate can
Slide 10: Calidi's Allogeneic Cell Platforms to deliver OV: NeuroNova (CLD-101)
Calidi’s Allogeneic Cell Platforms to deliver OV NEURONOVA (CLD-101) ) HB1.F3.CD21 Neural Stem Cells (Neuronova platform): CALDI © 2023 Calidi Biothera - Immortal and scalable neuronal stem cell line - Known safety profile in human trials - Possess an inherent ability to distribute throughout health
Slide 11: Calidi's Allogeneic Cell Platforms to deliver OV: SuperNova (CLD-201)
Calidi’s Allogeneic Cell Platforms to deliver OV SUPERNOVA (CLD-201) > — VP001 — Adult Adipose-derived Mesenchymal Stem Cells (SuperNova) MSC MCB proliferation/scalability profile - Derived from adipose (fat) tissue of healthy donors - Superior scalability and immunomodulatory properties - Known saf
Slide 12: Maximizing Therapeutic Responses with Directed Localized Administration
Maximizing Therapeutic Responses with Directed Localized Administration Directed — Localized administration CLD-101 (Neuronova) Y High therapeutic index of treated lesion/areas Completed Phase 1 Y Low toxicity Y Strong activation of local and systemic antitumor immunity ¥ In situ vaccination Vv Effi
Slide 13: Calidi's Systemic Cell-Based Virotherapy Development
Calidi’s based Systemic very Development ¥ Anew treatment option for advanced metastatic disease and un-targetable cancers using intratumoral administration Y Pre-clinical stage development © 2028 Cal Bciherepeutics, ne. 1 Company Propeary, Pens issued and pending CALIDi ° ™ eyes ee page 13
Slide 14: Targeting: Systemic Cell-Based Virotherapy
@) Targeting CF) Cell-based Virotherapy I > 1. Calidi’s Systemic Cell-Based Virotherapy: Untreated ‘Mouse model bearing 3 different solid tumor indications a) Resistant to rapid inactivation by humoral immunity. Tumor Indication b) This innovative approach effectively targets all tumor sites tested
Slide 15: Immunomodulation
3. lmmunomodulation % of CD3 Cells mm CD8+ other ma CD4eff ™ Treg Cell-Based Virotherapy Alters the Composition of Tumor-infiltrating 100: Lymphocytes in All Targeted distant site (Metastasis) (N=10 tumors) 80: 60: . ial . “Therapy induces a significant increase in the CD8-T cytotoxic population whi
Slide 16: Clinical revolution: new therapeutic level
Clinical revoluti new therapeutic level ) Aiming to provide safe and tolerable therapeutic approach Cell-based Oncolytic ; a A Off-the-shelf platform. Using proprietary, scalable, Vi roth era p les; commercially viable state-of-the-art approach. Multiple GMP lots already manufactured and in clinical
Slide 17: Antonio F. Santidrian, PharmD, PhD
Antonio F. Santidrian, PharmD, PhD Chief Scientific Officer Mobile: +1 858 405 5829 email: asantidrian@calidibio.com en eel = : Alidi Biotherapeutics, Inc *' = a 4475 Executive Drive, Suite 200 \ ‘. . . “] San Diego, CA92121 USA a www.calidibio.com
Calidi Biotherapeutics — Investor Presentation (December 2023) on 6ix